Oncorena has completed all preclinical studies and has initiated a Phase I/II clinical trial. The clinical Phase I/II trial protocol has been developed in collaboration with Karolinska University Hospital in Stockholm, Sweden.
Oncorena has received regulatory approval by the Swedish Medical Products Agency to start the first clinical trial of ONC175 (orellanine) in patients with metastatic renal cancer at Centre for Clinical Cancer Studies at the Karolinska University Hospital in Stockholm, Sweden. The study will subsequently be expanded to other countries.
For more information and contact
If you have patients with advanced renal cancer who are on chronic dialysis and who may be eligible for inclusion in Oncorena’s clinical program, please contact firstname.lastname@example.org.